Overcoming barriers that inhibit proper treatment of anemia

Slides:

Advertisements

Similar presentations

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Advertisements

Beta blockers in the management of chronic kidney disease

Iron indices: What do they really mean?

Plasma sodium and hypertension

A. Besarab Kidney International Volume 69, Pages S13-S18 (May 2006)

Anemia management in chronic kidney disease

American Journal of Kidney Diseases

Volume 56, Pages S95-S98 (November 1999)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Szu-Chun Hung, Der-Cherng Tarng Kidney International

Membranous nephropathy: When and how to treat

Progression of renal failure and hypertensive nephrosclerosis

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Volume 72, Issue 10, Pages (November 2007)

End-stage renal failure from asymptomatic bilateral ureteric stones

Volume 70, Pages S21-S25 (December 2006)

Volume 75, Issue 10, Pages (May 2009)

Homocysteine and risk in end-stage renal disease: a matter of context

Volume 72, Issue 6, Pages (September 2007)

Anemia as a risk factor for chronic kidney disease

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

A new era in phosphate binder therapy: What are the options?

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 73, Pages S81-S86 (April 2008)

Volume 70, Issue 11, Pages (December 2006)

Joseph W. Eschbach, John W. Adamson Kidney International

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 71, Issue 11, Pages (June 2007)

The epidemiology of chronic kidney disease

Benefits of preserving residual renal function in peritoneal dialysis

Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.

Study of Heart and Renal Protection (SHARP)

Volume 73, Pages S5-S17 (April 2008)

Volume 71, Issue 6, Pages (March 2007)

Volume 69, Issue 3, Pages (February 2006)

Volume 70, Issue 12, Pages (December 2006)

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Blood pressure targets in hemodialysis patients

Fructose intake as a risk factor for kidney stone disease

The third World Kidney Day: Looking back and thinking forward

Volume 72, Issue 2, Pages (July 2007)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Microbiology and outcomes of peritonitis in North America

AGEs in foods: Do they play a role in uremia?

Volume 87, Issue 1, Pages (January 2015)

Volume 70, Issue 1, Pages (July 2006)

The kidney, a cardiovascular risk marker, and a new target for therapy

Counteracting progression of renal disease: A look into the future

Neurogenic factors and hypertension in renal disease

Clinical benefits of slowing the progression of renal failure

Organ transplantation goes to the movies

Volume 70, Pages S84-S90 (November 2006)

Atherosclerotic renal artery stenosis and reconstruction

The Danish Renal Biopsy Register

Is it the low-protein diet or simply the salt restriction?

Charles A. Herzog Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 71, Issue 9, Pages (May 2007)

Volume 70, Issue 5, Pages (September 2006)

The arrow of bioimpedance

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

T cells and T-cell receptors in acute renal failure

Strategies for iron supplementation: Oral versus intravenous

The International Pediatric Peritonitis Registry: Starting to walk

Volume 72, Issue 12, (December 2007)

Morphology of the heart and arteries in renal failure

A. Lauschke, U.K.M. Teichgräber, U. Frei, K.-U. Eckardt

Presentation transcript:

Overcoming barriers that inhibit proper treatment of anemia R. Agarwal Kidney International Volume 69, Pages S9-S12 (May 2006) DOI: 10.1038/sj.ki.5000403 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Relative benefits and risks of EPO and i.v. iron therapy. NO=nitric oxide; HTN=hypertension; PDGF=platelet-derived growth factor; VSMC=vascular smooth muscle cells.1 Kidney International 2006 69, S9-S12DOI: (10.1038/sj.ki.5000403) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Blood pressure in rats with chronic renal failure (CRF) treated with either placebo, EPO, or EPO coupled with dietary iron deficiency (Fe def), 4 weeks after nephrectomy. The EPO-treated groups showed significant rise in blood pressure compared with the placebo-treated groups. Arrow indicates beginning of EPO or placebo treatment. Reprinted with permission from Am J Physiol. 1996; 271: E113–E122.22 Kidney International 2006 69, S9-S12DOI: (10.1038/sj.ki.5000403) Copyright © 2006 International Society of Nephrology Terms and Conditions